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Molecular determinants of P2Y2 receptor desensitization and sequestration have been investigated. Wildtype P2Y2 receptors and a series of five C-terminal truncation mutants of the receptor were epitope-tagged and
stably expressed in 1321N1 cells. These constructs were
used to assess the importance of the intracellular C terminus on 1) UTP-stimulated increases in intracellular
calcium concentration, 2) homologous desensitization of
the receptor, and 3) agonist-induced decreases in cellsurface density (receptor sequestration) of epitopetagged receptors using fluorescence-activated cell sorting. The potency and efficacy of UTP were similar for
the wild-type and all mutant P2Y2 receptors. Truncation
of 18 or more amino acids from the C terminus increased
by ;30-fold the concentration of UTP necessary to desensitize the receptor. Both the rate and magnitude of
UTP-induced receptor sequestration were decreased
with progressively larger truncations of the C terminus.
Furthermore, the recovery from sequestration was
slower for the most extensively truncated receptor.
Complete desensitization was obtained with >50% of the
original receptor complement remaining on the cell surface. Protein kinase C activation, which desensitizes the
P2Y2 receptor, had no effect on sequestration, consistent with the ideas that desensitization and sequestration are discrete events and that agonist occupancy is
required for receptor sequestration.

Responses to extracellular nucleotides are mediated by P2
receptors that belong to two receptor superfamilies: P2Y G
protein-coupled receptors (GPCRs)1 and P2X ligand-gated ion
channels. Multiple P2Y subtypes have been classified pharmacologically and molecularly and are predominantly linked to
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activation of phospholipase C and increased levels of inositol
1,4,5-trisphosphate and diacylglycerol, leading to elevations in
the intracellular free calcium concentration ([Ca21]i) and the
activation of protein kinase C (PKC) (1– 4). The P2Y2 nucleotide receptor subtype (formerly the P2U receptor) is distinguished pharmacologically from the other known mammalian
P2Y receptor subtypes by the equal potency and efficacy of the
naturally occurring agonists ATP and UTP.
Activation of P2Y2 receptors present in airway epithelium
increases Cl2 secretion through Ca21-dependent and outwardly rectifying Cl2 channels (5). It has been shown that
P2Y2 receptor activation by UTP in airway epithelia of cystic
fibrosis patients can increase Cl2 secretion, thereby effectively
bypassing the defective cAMP-dependent Cl2 transport (6).
Like other members of the GPCR superfamily, P2Y2 receptors
undergo agonist-induced desensitization (7), but little is known
about the mechanisms involved in desensitization of the P2Y2
receptor. It seems likely that a fuller understanding of desensitization and the signaling pathways that affect the P2Y2
receptor may lead to improved therapies targeted to this
receptor.
Desensitization of GPCRs is a complex process involving
phosphorylation of the receptors by multiple protein kinases,
including G protein-coupled receptor kinases, cAMP-dependent
protein kinase, and PKC. The mechanisms of GPCR desensitization have been studied most extensively with the b2-adrenergic receptor (reviewed in Ref. 8). The activation of b2-adrenergic receptors by agonist results in G protein-coupled receptor
kinase-mediated phosphorylation of serine and threonine residues in the carboxyl-terminal tail (9). The subsequent agonistinduced increase of cyclic AMP can result in the phosphorylation of additional residues within the b2-adrenergic receptor by
protein kinase A. Phosphorylation of b2-adrenergic receptors
leads to desensitization and sequestration of the receptors from
the cell surface, where they can no longer bind hydrophilic
ligands and apparently undergo dephosphorylation prior to
recycling to the cell membrane (10 –13). Prolonged exposure to
agonist results in down-regulation of the receptor, which is a
decrease in receptor number that requires new protein expression to reestablish receptor levels.
We investigated the role of the serine- and threonine-rich C
terminus of the P2Y2 receptor in agonist-induced receptor desensitization and sequestration. The C terminus of the P2Y2
receptor contains two consensus phosphorylation sites for PKC
(another site is present in the third intracellular loop) and
possible sites for G protein-coupled receptor kinase-mediated
phosphorylation. To determine the role of the C terminus in
receptor desensitization and sequestration, truncation mutants of a P2Y2 receptor cDNA encoding an epitope-tagged
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protein were constructed by polymerase chain reaction (PCR).
The truncated receptor cDNAs were expressed in a clonal human 1321N1 astrocytoma cell line devoid of P2Y nucleotide
receptors. UTP-induced desensitization was compared in cells
expressing mutant or wild-type P2Y2 receptors. Cell-surface
receptor density and agonist-induced sequestration in 1321N1
cells were assessed by immunofluorescence detection of the
epitope-tagged receptors.
EXPERIMENTAL PROCEDURES

Mutagenesis, Epitope Tagging, and Subcloning—Wild-type murine
P2Y2 receptor cDNA was subcloned into the retroviral vector pLXSN at
the EcoRI/BamHI sites of the multiple cloning site. The open reading
frame of the wild-type P2Y2 receptor cDNA was modified to incorporate,
at the amino terminus of the expressed protein, the hemagglutinin (HA)
epitope (YPYDVPDYA) from influenza virus using PCR. The forward
and reverse HA primers were 59-gatcgtgaattctgatgtatccatatgatgttccagattatgctgcagcagacctggaaccctgg-39 and 59-gatcgtggatcccctgactgaggtgctatagccg-39, respectively. The PCR solution contained primers (0.7 mM
each), 10 ml of 103 Vent polymerase buffer (New England Biolabs Inc.,
Beverly, MA), 100 ng of template DNA, 2.5 units of Vent (exo2) polymerase, 0.25 units of Vent (exo1) polymerase, and 20 ml of dNTP mixture
(0.2 mM dATP, dCTP, dTTP, and dGTP) in a final volume of 100 ml. The
PCR parameters were as follows: 96 °C for 1 min, 62 °C for 1 min, and
72 °C for 2.5 min for 25 cycles. The PCR conditions were identical for
creation of the five truncation mutants. In each case, the HA epitope
was inserted using the forward HA primer and the following reverse
primers: 59-tgctagggatcccgctactatgtccgtcttgagtcgtcact-39 (truncation
mutant 1), 59-tgctagggatcccgtcatcagtcgtcactactgactgacaaatc-39 (truncation mutant 2), 59-tgctagggatcccgctactaacttccagctggtgtggactc-39 (truncation mutant 3), 59-tgctagggatcccgtcatcacaaatctttcctcacagttctgttag-39
(truncation mutant 4), and 59-gcatcggatcctcatcagttaggcctgtgcaggccc-39
(truncation mutant 5). After verification of the PCR amplification by
agarose gel electrophoresis, the products were purified using a PCR
Wizard kit (Promega, Madison, WI). The purified PCR products and
pLXSN DNA were digested overnight with EcoRI and BamHI and
ligated together, followed by transformation of competent Escherichia
coli and identification of positive clones (14). All mutant DNAs were
sequenced on both strands to ensure that mutagenesis had occurred as
predicted, using an ABI Prism automated sequencing apparatus (Perkin-Elmer) and fluorescence dideoxynucleotide technology.
Cell Culture—Human 1321N1 cells were transfected with HA-tagged
murine P2Y2 receptor cDNA (P2Y2-1321N1 cells), using the pLXSN
retroviral vector, as described previously (15). The P2Y2-1321N1 cells
were grown to a density of ;5 3 106 cells/75-cm2 flask in Dulbecco’s
modified Eagle’s medium supplemented with 5% fetal bovine serum,
100 units/ml penicillin, 100 mg/ml streptomycin, and 500 mg/ml Geneticin (G418, Life Technologies, Inc.) at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. The day prior to use of the cells, the
growth medium was replaced with G418-free medium.
Calcium Measurements—Changes in [Ca21]i were detected by dualexcitation spectrofluorometric analysis of P2Y2-1321N1 cell suspensions loaded with fura-2 as described previously (16, 17). Cells were
assayed in 10 mM Hepes-buffered saline (pH 7.4) containing 1 mM CaCl2
and 1 mM MgCl2 unless indicated otherwise. Desensitization experiments were performed by incubating P2Y2-1321N1 cell suspensions
with varying concentrations of UTP for 5 min at 37 °C. The cells were
pelleted in a microcentrifuge and resuspended in 2 ml of buffer. The
EC50 value of UTP, determined during the concentration-response experiments (see Fig. 3), was used to re-challenge the cells. Concentration-response data were analyzed with the Prism curve fitting program
(GraphPAD Software for Science, San Diego, CA).
Sequestration Assays—P2Y2-1321N1 cells, grown to 80% confluency
in 35-mm2 dishes, were incubated with UTP (Amersham Pharmacia
Biotech) or phorbol 12-myristate 13-acetate (PMA; Sigma) for the times
and at the concentrations indicated in the figure legends. Control cells
were incubated without UTP (to allow an estimation of the total cellsurface complement of P2Y2 receptors) for 180 min.
The P2Y2-1321N1 cells were washed with 2 ml of ice-cold Hepesbuffered saline (pH 7.4) and incubated at 4 °C for 1 h with gentle
rocking in 1 ml of Hepes-buffered saline containing 10 mg of anti-HA
antibody 12CA5 (Boehringer Mannheim) that was affinity-purified as
follows. The antibody was added to a HiTrap protein G column (Amersham Pharmacia Biotech) equilibrated with 20 mM phosphate buffer
(pH 7.5) and eluted with 1-ml fractions of 100 mM glycine (pH 2.75). The
eluted fractions were immediately neutralized with 1 M Tris buffer (pH

8.5), dialyzed against phosphate-buffered saline (PBS), and stored for
use at a protein concentration of 1.5 mg/ml as estimated by a modification (18) of the method of Lowry et al. (19).
Cells incubated with antibody 12CA5 were washed with 2 ml of
Dulbecco’s PBS and incubated in 1 ml of Dulbecco’s PBS containing 10
ml of Fc-specific fluorescein isothiocyanate-labeled goat anti-mouse antibody (Sigma) in the dark at 4 °C with gentle rocking for 1 h. Control
cells were incubated with primary or secondary antibody alone to detect
nonspecific fluorescence. The P2Y2-1321N1 cells were washed with 2 ml
of Dulbecco’s PBS and detached in 2 ml of Hepes-buffered saline (pH
7.4) containing 2 mM EDTA. The cells were centrifuged and resuspended in 1 ml of 1% (v/v) formaldehyde in PBS and incubated in the
dark at 4 °C for 10 min.
Cells were centrifuged and resuspended in 0.5 ml of PBS and analyzed on an EPICS 753 flow cytometer (Coulter Corp., Hialeah, FL) with
a 5-watt argon laser tuned at 488 nm using 150-milliwatt output. The
instrument was optically aligned using DNA-Check fluorospheres
(Coulter Corp.) with the coefficients of variation #2%. For each analysis, 10,000 cells were collected using a dual-parameter histogram of
forward angle light scatter versus log 90° light scatter to gate out debris.
Integral green fluorescence emission (525 band path filter) of fluorescein isothiocyanate-labeled cells was displayed as a single-parameter
histogram on a three-decade log scale. Data analysis was performed
using EASY2 software (Coulter Corp.). Fluorescence intensity was used
as a measure of differences in receptor density on the cell surface for the
various receptor constructs. The computer cursor was set at a point
representing half the peak width at half the peak height, and the
channel number of this position was noted as the fluorescence intensity
of the histogram. Fluorescence intensity was measured after logarithmic amplification with the use of a three-decade log scale, but illustrated on a linear scale of 253 channels or 85.33 units/decade. Fluorescence intensity (FI) was converted to linear arbitrary units (LAU) using
the following formula: LAU 5 10(FI/85.33). LAU was corrected for fluorescence due to secondary antibody alone. Cells expressing wild-type or
mutant P2Y2 receptors that were not incubated with UTP but were
incubated with antibody 12CA5 and secondary antibody were considered to have the maximum number of receptor molecules on the cell
surface.
Calculation of Relative Receptor Densities—Cells expressing P2Y2
receptors were diluted from 1:2 to 1:8 with nontransfected 1321N1 cells,
and the amount of fluorescein isothiocyanate fluorescence was measured in a Spex dual-excitation/emission spectrofluorometer using 488
and 525 nm for the excitation and emission wavelengths, respectively.
Determinations of total protein/ml of cells were made using a modification (18) of the method of Lowry et al. (19). A standard curve of
fluorescence was constructed with HEK-293 cells heterologously expressing N-terminally HA-tagged b2-adrenergic receptors (Bmax 5 500
fmol/mg of total cell protein (20)) diluted with nontransfected HEK-293
cells.
RESULTS

Five cDNAs encoding P2Y2 receptors with different length
C-terminal truncations (Fig. 1) were constructed by PCR and
expressed in 1321N1 cells to determine the role of the C terminus in agonist-induced desensitization of receptor-mediated
calcium mobilization and receptor sequestration. The most extensively truncated receptor (truncation mutant 5) lacks two of
three protein kinase C consensus phosphorylation sites and
potential sites of phosphorylation by G protein-coupled receptor kinase present in the intracellular domains of the wild-type
P2Y2 receptor.
Recombinant P2Y2 Receptor Expression Levels in 1321N1
Cells—In the absence of an established method to detect P2Y2
receptors on the cell surface, all receptor constructs were Nterminally tagged with an epitope of the HA antigen from
influenza virus. The fluorescence intensities of cells expressing
the epitope-tagged P2Y2 receptor constructs were determined
by flow cytometry, and the resulting scans were superimposed
(Fig. 2). These data indicate similar fluorescence intensities for
each receptor, with truncation mutant 3 and wild-type receptors representing the high and low values, respectively, of the
range of receptor expression. Thus, the expression of the six
receptor constructs was approximately the same, with a maximal 2-fold difference in receptor density (Table I). The number
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FIG. 1. Predicted secondary structure of the wild-type P2Y2 receptor
and positions of truncation mutant
receptors. All recombinant receptors
used in this study were N-terminally
tagged with the HA epitope. The positions
of the truncations made and the PKC consensus phosphorylation sites (*) are
shown.

FIG. 2. Expression levels of recombinant receptors. Flow cytometry scans
of HA-tagged wild-type (HAWT) and truncation mutant P2Y2 receptors expressed
in 1321N1 astrocytoma cells were superimposed. The wild-type and truncation
mutant 3 receptors represent the low and
high range, respectively, of expression
levels for recombinant receptors in
1321N1 cells.

of HA-tagged wild-type P2Y2 receptors in 1321N1 cells was
estimated by comparison with the fluorescence intensity due to
HA-tagged b2-adrenergic receptors (500 fmol/mg of total protein) in HEK-293 cells (20). The b2-adrenergic receptor density
was determined to be 32,667 6 6692 receptors/cell compared
with 22,767 6 9753 receptors/cell for the wild-type P2Y2
receptor.
Progressive Truncations of the C Terminus Result in Altered

Agonist Concentration-effect Curves for Receptor Desensitization—As shown in Fig. 3 (A–F), wild-type and truncated P2Y2
receptors had similar concentration-effect curves for UTP-induced increases in [Ca21]i. The similarity of the EC50 and
maximal response values with UTP for the six P2Y2 receptor
constructs (Fig. 3 and Table I) indicates that the truncations
had no marked effect on receptor activation and signaling when
the various constructs were expressed at approximately the
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TABLE I
EC50/IC50 values of agonist-induced activation and desensitization of [Ca21]i, together with receptor expression and estimated t1⁄2 values and
maximum levels of receptor sequestration
Concentration responses (EC50 and IC50) were determined from the data collected in Fig. 3 (A–F). Normalized receptor expression levels were
calculated by determining the ALI (n 5 3) for each receptor construct and comparing each value to the wild-type receptor, which was regarded as
1. Estimated t1⁄2 values of sequestration were from Fig. 4 (A–F). Maximal receptor sequestration (the percentage of receptor complement removed
from the cell surface) was determined from the data used to construct Fig. 4 (A–F).
Recombinant
P2Y2 receptors

Concentration-response
EC50 of UTP
(activation)

Concentration-response
IC50 of UTP
(desensitization)

Normalized receptor
expression (wildtype 5 1)

0.43 6 0.1
1.23 6 0.8
3.37 6 1.8
7.78 6 4.8
12.3 6 3.3
9.75 6 5.1

1.00 6 0.10
1.07 6 0.15
1.95 6 0.18
2.00 6 0.15
1.09 6 0.17
1.72 6 0.36

mM

Wild-type
Truncation
Truncation
Truncation
Truncation
Truncation

1
2
3
4
5

0.25 6 0.03
0.47 6 0.07
0.61 6 0.23
0.05 6 0.01
0.10 6 0.02
0.18 6 0.04

Estimated t1⁄2 values
of sequestration

Maximal receptor
sequestration
after 180 min

min

%

,5
5–10
45
60
150
120

90 6 1
90 6 1
80 6 1
80 6 2
50 6 2
67 6 14

FIG. 3. UTP concentration-effect
curves for activation and agonist-induced desensitization of wild-type
and truncation mutant P2Y2 receptors. Cells expressing recombinant HAtagged P2Y2 receptors were prepared, and
[Ca21]i was measured in response to the
indicated concentrations of UTP (f) as
described under “Experimental Procedures.” [Ca21]i is expressed as a percentage of the maximal response to allow comparisons among different receptor
constructs. The maximal increases in
[Ca21]i in response to UTP obtained for
each receptor construct were as follows:
wild-type, 282 6 82 nM (A); truncation
mutant 1, 733 6 13 nM (B); truncation
mutant 2, 341 6 132 nM (C); truncation
mutant 3, 341 6 130 nM (D); truncation
mutant 4, 276 6 33 nM (E); and truncation mutant 5, 318 6 80 nM (F). Desensitization (Œ) was assessed by incubating
1321N1 cells expressing the different receptor constructs for 5 min with the indicated concentrations of UTP, followed by
re-challenging with the EC50 value of
UTP, determined in the receptor activation experiments (see Table I). The data
presented are expressed as a percentage
of the peak calcium response to the EC50
value of UTP in cells that were not preincubated with the agonist. The peak values
were as follows: wild-type, 176 6 43 nM
(A); truncation mutant 1, 247 6 43 nM (B);
truncation mutant 2, 252 6 97 nM (C);
truncation mutant 3, 240 6 84 nM (D);
truncation mutant 4, 231 6 47 nM (E);
and truncation mutant 5, 420 6 188 nM
(F). The values shown are the mean 6
S.E. of three experiments.

same density. The truncated receptors exhibited rapid and
transient increases in [Ca21]i in response to UTP, followed by
a return to base-line levels within 3 min (data not shown),
similar to the wild-type receptor. The desensitization of the
calcium response to UTP was determined for each receptor
following a 5-min preincubation with the indicated concentration of UTP (Fig. 3). Progressive truncations of the C terminus

increased the IC50 values for UTP-induced desensitization to a
maximum of 25-fold with truncation mutant 4 (Table I).
Truncations of the C Terminus Decrease Receptor Sequestration—Fig. 4 shows that .80% of the wild-type receptors were
sequestered within 10 min. The t1⁄2, the time at which 50% of
the cell-surface receptor complement is sequestered, was ,5
min. Progressive truncations of the C terminus of the P2Y2

P2Y2 Receptor Truncations Alter Desensitization/Sequestration

29441

FIG. 4. Time course for sequestration of recombinant P2Y2 receptors
expressed in 1321N1 cells. Cells expressing recombinant P2Y2 receptors
were incubated with 1 mM UTP for the
indicated times, and receptor density on
the cell surface was determined as described under “Experimental Procedures.” Cells expressing recombinant
P2Y2 receptors and incubated in the absence of UTP were regarded as having the
full complement of cell-surface receptors,
from which the percentage of receptors
present on the cell surface following UTP
incubation was calculated. The values
shown are the mean 6 S.E. of 10 experiments for the wild-type P2Y2 receptor,
seven experiments for truncation mutant
5, and three experiments for truncation
mutants 1– 4.

receptor increased the t1⁄2 for sequestration. For the most truncated forms of the receptor (truncation mutants 4 and 5), the t1⁄2
values were ;25-fold greater, and at least 35% of the receptors
remained on the cell surface after 180 min. UTP concentrationeffect curves show that 50% of the wild-type receptors were
sequestered after a 10-min incubation with ;6 mM UTP,
whereas sequestration of 50% of the truncation mutant 5 receptors required a 120-min incubation with 1 mM UTP (Fig. 5).
Hydrolysis of UTP by 1321N1 cells was determined by HPLC
analysis to be negligible, with 96% of the UTP remaining after
3-h incubation (data not shown). The original UTP stock solution contained a similar percentage of UTP, with 4% contamination with UDP. We were thus unable to detect any significant hydrolysis of UTP under these experimental conditions,
unlike Lazarowski et al. (21), who demonstrated significant
ecto-apyrase activity in 1321N1 cells. It is possible that, during
our experiments, too much UTP and too few 1321N1 cells were
present to demonstrate significant hydrolysis of nucleotide.
P2Y2 Receptor Sequestration Is Reversible—The reversibility
of sequestration of the wild-type P2Y2 receptor was determined
after preincubating cells for 10 min with 1 mM UTP. Following

incubation of the cells for various times in the absence of
agonist, cell-surface receptor expression was determined. As
shown in Fig. 6, recovery was time-dependent and nearly complete (;90%) after 240 min. Half of the receptor complement
returned to the cell surface in ;60 min.
UTP-induced Receptor Desensitization and Sequestration
Are Distinct Events—Fig. 7 illustrates the relationship between
agonist-induced desensitization and receptor sequestration for
the wild-type and truncation mutant 5 receptors. It is apparent
for both receptors that 50% of the cell-surface receptor complement was still present when the UTP-induced increase in
[Ca21]i was desensitized. Furthermore, the wild-type and truncation mutant 5 P2Y2 receptors had nearly all of the receptor
complement on the cell surface when 50% of the UTP-induced
calcium response was desensitized.
The effects of the protein kinase C activator PMA on desensitization of UTP-stimulated increases in [Ca21]i were examined in cells expressing the wild-type and truncation mutant 5
P2Y2 receptors. Fig. 8 shows that the wild-type and truncation
mutant 5 receptors have similar IC50 values (35 6 17 and 62 6
35 nM, respectively) for PMA-induced desensitization. How-
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FIG. 7. Relationship between agonist-induced desensitization
of recombinant P2Y2 receptors and the percentage of receptors
remaining on the surface of 1321N1 astrocytoma cells. Values for
UTP-induced desensitization (after a 10-min preincubation with agonist) of calcium mobilization by wild-type (E) and truncation mutant 5
(l) P2Y2 receptors expressed in 1321N1 cells were plotted against the
percentage of receptors remaining on the cell surface after incubation
with the concentrations of UTP indicated in Fig. 5( A and B).

FIG. 5. Concentration-dependent effect of UTP on sequestration of recombinant P2Y2 receptors. A, 1321N1 cells expressing the
wild-type P2Y2 receptor were incubated with the indicated concentrations of UTP for 10 min, and receptor density on the cell surface was
determined as described under “Experimental Procedures.” B, 1321N1
cells expressing truncation mutant 5 were incubated with the indicated
concentrations of UTP for 120 min, and receptor sequestration was
determined as described for A. The values shown are the mean 6 S.E.
of data from three experiments.

FIG. 6. Time course of recovery of the cell-surface P2Y2 receptor complement. 1321N1 cells expressing the wild-type P2Y2 receptor
were incubated with 1 mM UTP for 10 min. UTP was removed; the
medium was replaced; and the cells were incubated at 37 °C in 5% CO2
and allowed to recover for the indicated times before the percentage of
receptors remaining on the cell surface was determined as described
under “Experimental Procedures.” The receptor complement is expressed as a percentage of the level of receptors present in 1321N1 cells
incubated in the absence of UTP. The values shown are the mean 6 S.E.
from three experiments.

ever, truncation mutant 5 required greater concentrations of
PMA to induce desensitization. For example, truncation mutant 5 was ;65% desensitized at 1 mM PMA, a concentration
that fully desensitized the wild-type receptor. These data indicate a strong desensitizing effect of PMA on UTP-stimulated
Ca21 mobilization.

FIG. 8. Concentration-effect curves for PMA-induced desensitization of wild-type and truncation mutant 5 P2Y2 receptors.
Cells expressing recombinant HA-tagged P2Y2 receptors were prepared, and [Ca21]i was measured and desensitization was assessed as
described under “Experimental Procedures” by incubating 1321N1 cells
expressing the different receptor constructs (wild-type (Œ) and truncation mutant 5 (f) P2Y2 receptors) for 5 min with the indicated concentrations of PMA, followed by re-challenging with the EC50 value of UTP,
determined in receptor activation experiments (Fig. 3). [Ca21]i is expressed as a percentage of the maximal response to allow comparisons
of the receptor constructs. The maximal increases in [Ca21]i in response
to UTP obtained for each receptor construct were as follows: wild-type,
189 6 43 nM; and truncation mutant 5, 196 6 55 nM. The values shown
are the mean 6 S.E. from three experiments.

FIG. 9. Effect of PKC activation on wild-type P2Y2 receptor
sequestration. 1321N1 cells expressing the wild-type P2Y2 receptor
were incubated for periods of up to 180 min with 1 mM UTP (Œ), 1 mM
UTP and 1 mM PMA (), or 1 mM PMA (f), and the percentage of
receptors remaining on the cell surface was determined as described
under “Experimental Procedures.” The receptor complement is expressed as a percentage of the level of receptors present in 1321N1 cells
incubated in the absence of UTP. The values shown are the mean 6 S.E.
from three experiments.

P2Y2 Receptor Truncations Alter Desensitization/Sequestration
However, exposure of cells to 1 mM PMA for times ranging
from 5 to 180 min failed to induce sequestration of wild-type
P2Y2 receptors (Fig. 9). Furthermore, co-incubation with 1 mM
PMA and 1 mM UTP produced a pattern of sequestration similar to that obtained with UTP alone. These findings suggest no
role for PKC in the sequestration of the P2Y2 receptor and thus
dissociate receptor desensitization from sequestration.
DISCUSSION

Desensitization of the G protein-coupled P2Y2 receptor can
attenuate responses to nucleotides, which may impair the therapeutic effects of nucleotides in treatment of diseases such as
cystic fibrosis. G protein-coupled receptor desensitization can
involve several protein kinases, including protein kinase A,
PKC, and G protein-coupled receptor kinases (reviewed in Ref.
8). However, the pathway involved in P2Y2 receptor desensitization is not well understood. P2Y2 receptor activation is coupled to phospholipase C, leading to the production of diacylglycerol, an activator of PKC. The presence of three consensus
sites for phosphorylation by PKC and possible sites for G protein-coupled receptor kinase phosphorylation in the intracellular domain of the P2Y2 receptor prompted us to investigate the
role of the serine/threonine-rich C terminus in agonist-induced
P2Y2 receptor desensitization.
It has been established in this study that the recombinant
P2Y2 receptor expressed in 1321N1 cells desensitizes like the
endogenous receptor in bovine aortic endothelial cells (7). Desensitization of the P2Y2 receptor occurs in response to UTP or
activation of PKC with PMA, although in some cells, PKC may
not mediate P2Y2 receptor desensitization (22).
The lack of a reliable radioligand binding assay and antibodies to the endogenous P2Y2 receptor necessitated the incorporation of the HA epitope of influenza virus at the N terminus of
the receptor to monitor sequestration with the 12CA5 monoclonal antibody. Truncation of 30 amino acids from the C terminus of the P2Y2 receptor (truncation mutant 5) increased the
concentration of UTP required for receptor desensitization and
decreased the ability of these receptors to sequester as efficiently as the wild-type P2Y2 receptor. This trend was also
exhibited with truncation mutants 3 and 4. However, truncation mutant 2 had a similar UTP concentration response for
desensitization, but different sequestration properties compared with the wild-type P2Y2 receptor, whereas truncation
mutant 1 desensitized and sequestered like the wild-type receptor. The cause for the change in sequestration properties
that occurred between truncation mutants 1 and 2 requires
further investigation, but may involve the loss of one or more
essential amino acids from truncation mutant 2 that impact on
sequestration, but not desensitization. Clearly, these changes
do not affect receptor activation since UTP-induced increases
in [Ca21]i for all the recombinant P2Y2 receptor constructs had
similar concentration-response curves. The wild-type P2Y2 receptor lacks any cysteine residues in its C terminus that are
apparently required for palmitoylation of the b2-adrenergic
receptor (23, 24) and the formation of tertiary structure required for agonist-induced receptor desensitization (25).
The wild-type P2Y2 receptor expressed in 1321N1 cells desensitizes and sequesters in a time-dependent manner similar
to other GPCRs, and although the P2Y2 receptor recovers from
desensitization like other GPCRs, its recovery from sequestration is slower (11, 26). It may be that the presence of the HA
epitope affects the sequestration kinetics of the P2Y2 receptor,
but until reliable radioligands are developed for this receptor,
we are unable to address this question. Although de novo
protein synthesis may be responsible for recovery of some receptor activity, resensitization is more likely due to receptor
recycling given the short incubation period with UTP. How-
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ever, recovery from receptor sequestration was difficult to evaluate in cells expressing truncation mutant 5 because of the
necessity to incubate these cells for 180 min (a period that may
involve receptor down-regulation) to get adequate sequestration. Experiments on transcriptional regulation of the endogenous P2Y2 receptor will be necessary to determine the mechanisms of recovery from receptor down-regulation.
Truncations of the carboxyl-terminal tail of G protein-coupled receptors can have a wide range of effects on receptor
desensitization and sequestration. Truncation of the terminal
45 amino acids of the angiotensin II type 1A receptor inhibited
receptor internalization with no effect on radioligand binding,
downstream signaling, or agonist-induced desensitization (27).
Removal of 72 of 86 amino acids from the C terminus of the
serotonin type 2 receptor had no effect on the ability of the
receptor to stimulate phospholipase C or to be internalized
even though three of five PKC consensus phosphorylation sites
and potential G protein-coupled receptor kinase phosphorylation sites were removed (28). However, the authors noted the
presence in the truncated and wild-type 5HT2 receptors of the
consensus NPXXY sequence, in which the tyrosine residue has
been reported to be essential for b2-adrenergic receptor sequestration. In contrast, Thomas et al. (27) have reported the presence of an NPXXY sequence in an internalization-resistant
mutant of the angiotensin II type 1A receptor. The P2Y2 receptor has a DPXXY sequence that remains after the most radical
truncation (truncation mutant 5), and it will be of interest to
see if this tyrosine residue has any role in receptor
sequestration.
Another study of the phospholipase C-linked G protein-coupled a1B-adrenergic receptor indicated the importance of the C
terminus in agonist-induced receptor phosphorylation and desensitization (29). A 147-amino acid truncation of the C terminus of the a1B-adrenergic receptor did not decrease agonistinduced inositol 1,4,5-triphosphate accumulation compared
with the wild-type a1B-adrenergic receptor. However, the truncated receptor was resistant to desensitization and was not
phosphorylated in response to activation by its ligand, epinephrine. The truncated a1B-adrenergic receptor was able to sequester, but more slowly than the wild-type receptor.
Removal of 43 amino acids from the C terminus of the
lutropin/choriogonadotropin receptor (30) or 48 amino acids
from the C terminus of the b2-adrenergic receptor (31) led to a
decrease in agonist-induced uncoupling of the receptors from
adenylyl cyclase. Compared with the wild-type b2-adrenergic
receptor, the truncation mutant required longer periods of agonist exposure to desensitize, presumably indicating the importance of b-adrenergic receptor kinase phosphorylation sites
that were lost upon receptor truncation.
It will be of interest to investigate the specific amino acid
residues of the P2Y2 receptor that are involved in both desensitization and sequestration of this receptor. Fredericks et al.
(9) identified G protein-coupled receptor kinase phosphorylation sites in the b2-adrenergic receptor and found similarities
between these sites and those found in rhodopsin. The most
amino-terminal phosphorylation site in both rhodopsin and the
b2-adrenergic receptor has pairs of acidic residues at its aminoterminal side. Truncation mutant 3 of the P2Y2 receptor truncates the receptor directly after two acidic residues and directly
before a serine residue. It is tempting to speculate the importance of these amino acids in P2Y2 receptor function since
truncation mutant 3 is the least truncated form of the P2Y2
receptor used in this study that required an increased concentration of UTP to induce desensitization compared with the
wild-type receptor.
Very few studies have directly investigated the role of func-
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tionally important domains of P2Y receptors. Specific amino
acids in the transmembrane-spanning domains of the P2Y2 (32)
and P2Y1 (33) receptors have been shown to affect agonist
potency and specificity. The present study has defined the
importance of the C terminus of the P2Y2 receptor in desensitization and sequestration. Considering the widely varying
roles of the C terminus in G protein-coupled receptor functions,
future studies should better delineate the relevance of this
domain to P2Y2 receptor regulation. Studies are also needed to
fully evaluate the role of PKC and other protein kinases in the
desensitization and sequestration of the P2Y2 receptor. A complete understanding of the signaling pathways involved may
help minimize receptor desensitization and sequestration to
optimize nucleotide therapies, such as those proposed for cystic
fibrosis, that are directed at the P2Y2 receptor.
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